Heart failure & cardiomyopathies
Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial
Primary result · EF improvementResult — go to the resultBetween-group difference 3.3 percentage points 95% CI 0.2–6.4Authors' conclusion
A polypill for heart failure was associated with a significant improvement in cardiac function as compared with enhanced usual care.
Study context
- Population
- Adults with HF and LVEF ≤40%, predominantly underserved population187 (88%) in mITT analysis
- Participants
- 212 adults
- Comparison
- Polypill vs enhanced usual care
- Primary endpoint
- Ejection fraction as assessed by cardiac magnetic resonance imaging
- Follow-up
- 6 months
Methodological detailsopen-label, two centres
- Open-label
- Two centres
Primary result
EF improvement
Between-group difference
3.3 percentage points
95% CI 0.2–6.4
P = 0.039
Polypill vs Enhanced usual care
between-group difference 3.3 percentage points (95% CI 0.2–6.4); P = 0.039
As reported in the abstract
Secondary outcomes
| Outcome | Adjusted rate ratio (95% CI) | P value | |
|---|---|---|---|
| HF hospitalizations or ED visits · 60% lower rate | 0.40 (0.18–0.88) | P = 0.024 | |
| 0.20.5125Adjusted rate ratio (log scale) |
Adherence (blood concentrations of metoprolol and spironolactone)
P = 0.001
Safety
Adverse events
- Polypill well tolerated, fewer adverse events than enhanced usual care
Original publication
Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial. Nat Med. Published 2 July 2026. doi:10.
Summarised from the published abstract; every number is checked against it